What the trial was testing
The SURMOUNT-2 enrolled 938 patients with type 2 diabetes. The study was sponsored by Eli Lilly and Company and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
People taking tirzepatide lost up to 15% of their body weight over 72 weeks, compared to 3% with placebo.
Lancet (London, England) · 2023 · NCT04657003
These findings — that people on the higher dose lost 15% of their body weight versus 3% on placebo — were published in the Lancet (London, England) and represent the headline result of the study.
Researchers tracked outcomes across 938 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with type 2 diabetes, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Tirzepatide is FDA-approved for type 2 diabetes and weight management. It's available now under brand names including Mounjaro (for diabetes) and Zepbound (for weight management). If you have type 2 diabetes and are struggling with weight, talk to your doctor about whether tirzepatide might be right for you.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open type 2 diabetes trials
China Monogenic Diabetes Registry
This observational study aims to establish a digital registry, screening platform for patients with monogenic diabetes using internet-based and mobile application technologies. The primary objectives are to: Characterize the genetic landscape of monogenic diabetes in the Chinese population, including pathogenic variants and their distribution Participants will: * Enroll in the monogenic diabetes registry via mobile application or web-based platform * Undergo molecular genetic testing to establish a definitive diagnosis
Diabetic Nephropathy in People With Diabetes. Prevalence and Predictive Factors
a prospective, observational, multi-center study with a cohort of 300 patients with Type 2 diabetes and macroalbuminuria. Prospectively we will collect kidney biopsies and analyse the transciptome of the kidney tissue and other biomarkers from blood, faeces, urine, proteomic- and metabolomic profiles and DNA-variants. Thereby we hope to be able to discover molecular and clinical profiles, that can help us in the diagnosis of DKD, and to identify different risks of progression that can benefit from different forms of personalized treatment.